Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496355 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL12158808 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL12158787 | 1.00 | ADRB2 (0.58) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14301399 | 0.92 | ADRB2 (0.55) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14300964 | 0.92 | ADRB2 (0.55) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL11747826 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178271 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178277 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178269 | 0.85 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL15178341 | 0.85 | ADRB2 (0.47) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0763010-B1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | claimed |
| EP-0763010-A4 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | claimed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | claimed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | claimed |
| WO-2023062633-A1 | PROCESS FOR THE PREPARATION OF A SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-20 | — | — | WO | disclosed |
| US-RE43984-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2013-02-05 | — | — | US | disclosed |
| US-RE43844-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2012-12-04 | — | — | US | disclosed |
| US-8063251-B2 | Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts | AARTI HEALTHCARE LIMITED (IN) | 2011-11-22 | — | — | US | disclosed |
| US-8063251-B2 | Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts | AARTI HEALTHCARE LIMITED (IN) | 2011-11-22 | — | — | US | disclosed |
| US-20100204516-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | AARTI HEALTHCARE LIMITED (IN) | 2010-08-12 | — | — | US | disclosed |
| US-20100204516-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | AARTI HEALTHCARE LIMITED (IN) | 2010-08-12 | — | — | US | disclosed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0745068-A4 | HETEROARYL-SUBSTITUTED DEOXY GLYCERO-PHOSPHOETHANOLAMINES | CLARION PHARMACEUTICALS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0745068-A1 | HETEROARYL-SUBSTITUTED DEOXY GLYCERO-PHOSPHOETHANOLAMINES | CLARION PHARMACEUTICALS, INC. (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1996016041-A1 | HETEROARYL-SUBSTITUTED DEOXY GLYCERO-PHOSPHOETHANOLAMINES | CLARION PHARMACEUTICALS INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204516-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | FFAR4, ADRB1, NR1H4 | ADRB2 12/4885ADRB1 2/4885CYP1A2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.